Miami Cancer Institute, part of Baptist Health South Florida, has initiated several clinical trials based on treatments from initial emergency and experimental COVID-19 therapies.
A combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) demonstrated statistically significant improvement in overall survival, progression-free survival and objective response rate versus chemotherapy in patients with advanced endometrial cancer.
COSMIC-311, the phase III pivotal trial evaluating Cabometyx (cabozantinib) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has launched its fourth statewide cancer research initiative focused on increasing breast cancer education, facilitating access to genetic counseling and ensuring appropriate screening, follow-up for abnormalities and treatment for Black women who are at an increased risk for breast cancer.
A Roswell Park Comprehensive Cancer Center team led by Christine Ambrosone and Song Yao has found a distinct molecular signature in the tumor tissues of Black patients with breast cancer.
A growing number of women forgoing reconstruction after a mastectomy say they're satisfied with their choice, even as some did not feel supported by their physician, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center.
Scientists at the UCLA Jonsson Comprehensive Cancer Center describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip.
Postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from a clinical trial presented at the 2020 San Antonio Breast Cancer Symposium.
University of California, Los Angeles-led research shows that behavioral interventions, mindfulness meditation and survivorship education classes, are effective in reducing depressive symptoms in younger breast cancer survivors, who often experience the highest levels of depression, stress and fatigue that can persist for as long as a decade after their diagnosis.
The American Society of Clinical Oncology issued comprehensive recommendations to guide the cancer community's eventual recovery from the COVID-19 pandemic.
